|
30% of pharma executives expect business as usual, as they admit to expecting blockbuster-type launches to continue to be the norm within the pharmaceutical industry.
Big Biotech companies are demonstrating that they are in a better position than their pharmaceutical industry counterparts to compete in today’s more value-based healthcare market, says a new report.
India’s Supreme Court rejected Novartis’ patent application for the cancer drug Glivec yesterday. A victory for the Indian drug industry, but the result may have repercussions on India’s attempts to attract foreign investment
Pharmaceutical innovation – and breakthrough success – is assessed by looking at the percentage of a company’s sales that comes from products approved in the last 5 years. Yet, regardless of potential, new drugs grow slowly, and many firms are depending on ‘old reliables’ for sales revenue.
The Supreme Court heard a case on Tuesday which will decide whether generics firms can be held liable and sued over alleged design flaws in their medications.
AstraZeneca announced yesterday plans to reorganise its strategic research and development centres as it aims to establish itself as a global leader in biopharmaceutical innovation.
Today over 850 pharma professionals, doctors, payers and patients will descend on Spain’s second largest city for the world’s largest annual commercial pharmaceutical event.
Amgen has pled guilty in a federal court to charges of improper marketing of the anaemia drug Aranesp.
Big Pharma’s financial outlook may appear unsteady but are they more prepared than their generic counterparts?
30% of pharma executives expect business as usual, as they admit to expecting blockbuster-type...
Forceful efforts to thwart generic drug competition in France have landed multinational pharma firm...
In the largest US drug safety settlement to date with a generic drug manufacturer, agreement was...
